- Home
- GOSS vs TKNO Comparison
GOSS vs TKNO Comparison
Compare GOSS & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- TKNO
- Stock Information
- Founded
- GOSS 2015
- TKNO 1996
- Country
- GOSS United States
- TKNO United States
- Employees
- GOSS N/A
- TKNO N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- GOSS Health Care
- TKNO Health Care
- Exchange
- GOSS Nasdaq
- TKNO Nasdaq
- Market Cap
- GOSS 347.8M
- TKNO 256.9M
- IPO Year
- GOSS 2019
- TKNO 2021
- Fundamental
- Price
- GOSS $2.47
- TKNO $4.35
- Analyst Decision
- GOSS Strong Buy
- TKNO
- Analyst Count
- GOSS 4
- TKNO 0
- Target Price
- GOSS $8.50
- TKNO N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- TKNO 224.0K
- Earning Date
- GOSS 08-05-2025
- TKNO 08-07-2025
- Dividend Yield
- GOSS N/A
- TKNO N/A
- EPS Growth
- GOSS N/A
- TKNO N/A
- EPS
- GOSS N/A
- TKNO N/A
- Revenue
- GOSS $40,237,000.00
- TKNO $38,923,000.00
- Revenue This Year
- GOSS N/A
- TKNO $9.52
- Revenue Next Year
- GOSS $30.65
- TKNO $15.20
- P/E Ratio
- GOSS N/A
- TKNO N/A
- Revenue Growth
- GOSS N/A
- TKNO 11.40
- 52 Week Low
- GOSS $0.66
- TKNO $4.00
- 52 Week High
- GOSS $2.65
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- TKNO 43.35
- Support Level
- GOSS $2.38
- TKNO $4.22
- Resistance Level
- GOSS $2.65
- TKNO $4.94
- Average True Range (ATR)
- GOSS 0.15
- TKNO 0.29
- MACD
- GOSS 0.03
- TKNO -0.00
- Stochastic Oscillator
- GOSS 76.67
- TKNO 16.75
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.